ansuvimab
E468967
antiviral drug
biologic medicinal product
human monoclonal antibody
monoclonal antibody
therapeutic antibody
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
antiviral drug
ⓘ
biologic medicinal product ⓘ human monoclonal antibody ⓘ monoclonal antibody ⓘ therapeutic antibody ⓘ |
| actsOn |
Ebolavirus
NERFINISHED
ⓘ
Zaire ebolavirus NERFINISHED ⓘ |
| administeredAs | single-dose intravenous infusion ⓘ |
| antibodyType | IgG1 ⓘ |
| approvalYear | 2020 ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | J06BD09 ⓘ |
| belongsToClass |
Ebola virus–directed antibodies
ⓘ
antiviral monoclonal antibodies ⓘ |
| clinicalTrialContext | evaluated during Ebola virus disease outbreaks in Africa ⓘ |
| countryOfFirstApproval | United States of America NERFINISHED ⓘ |
| developedBy |
Mapp Biopharmaceutical
NERFINISHED
ⓘ
Ridgeback Biotherapeutics NERFINISHED ⓘ |
| distinguishedFrom |
REGN-EB3
NERFINISHED
ⓘ
ZMapp NERFINISHED ⓘ |
| hasMolecularTarget | Ebola virus envelope glycoprotein GP1,2 ⓘ |
| hasTradeName | Ebanga NERFINISHED ⓘ |
| indicatedFor |
Ebola virus disease due to Zaire ebolavirus
ⓘ
infection caused by Zaire ebolavirus ⓘ |
| indicationPopulation |
adults with Zaire ebolavirus infection
ⓘ
children with Zaire ebolavirus infection ⓘ |
| isMonotherapy | true ⓘ |
| isNotIndicatedFor |
post-exposure prophylaxis of Ebola virus disease
ⓘ
pre-exposure prophylaxis of Ebola virus disease ⓘ |
| isProtein | true ⓘ |
| isSingleComponentProduct | true ⓘ |
| legalStatusUS | prescription-only medicine ⓘ |
| mechanismOfAction |
binds to Ebola virus glycoprotein
ⓘ
neutralizes Ebola virus entry into host cells ⓘ |
| originSpecies | Homo sapiens NERFINISHED ⓘ |
| pharmacologicalClass | Ebola virus glycoprotein–directed monoclonal antibody ⓘ |
| reduces | mortality in Ebola virus disease patients ⓘ |
| regulatoryDesignation | orphan drug (US) ⓘ |
| regulatoryPathway | FDA approval under traditional approval pathway ⓘ |
| riskGroup | patients with confirmed Zaire ebolavirus infection ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets | Zaire ebolavirus glycoprotein ⓘ |
| therapeuticArea |
infectious diseases
ⓘ
viral hemorrhagic fevers ⓘ |
| usedFor |
treatment of Ebola virus disease
ⓘ
treatment of Zaire ebolavirus infection ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.